Major players in the cervical cancer diagnostics market are Abbott Laboratories, Becton, Dickinson and Co., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Hologic Inc., QIAGEN NV, Quest Diagnostics Inc., Siemens Healthineers AG, Zilico, and Guided Therapeutics.
The global cervical cancer diagnostics market is expected to grow from $7.227 billion in 2020 to $7.663 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $9.687 billion in 2025 at a CAGR of 6%.
The cervical cancer diagnostics market consists of sales of cervical cancer diagnostic devices and related services by entities (organizations, sole traders and partnerships) that produce cervical cancer diagnostics devices.Cervical cancer is a type of cancer that occurs in cells of the cervix.
These devices are used for the diagnosis of cervical cancer.
The increased adoption of HPV home testing kits is expected to be the new trend in the market.The home-based HPV testing kits help women in collecting samples and getting the results conveniently on their own without going to the lab for screening.
Therefore, companies are focusing on providing convenience to patients.For instance, in January 2019, Nurx, a consumer health and telemedicine company, introduced lab testing that allows women to easily and affordably monitor their risk of cervical cancer from the comfort of their home.
Similarly, in April 2019, Matter introduced three conceptual cervical cancer examinations through the Sukha project that help women carry out tests at home to break the stigma associated with cervical testing.
In November 2018, QIAGEN, a German-based leading supplier of specimen and assay systems for diagnostic techniques, applied testing, academic and pharmaceutical research, collaborated with Self-screen BV and released the QIAscreen HPV PCR Test, a CE-IVD molecular diagnostic test for the detection of 15 recognized high-risk human papillomavirus (HPV) genotypes, which is considered to be the cause of cervical cancer. Self-screen BV is a VU University Medical Centre’s spinoff company based in the Netherlands.
The rising adoption of cervical cancer diagnostic tests for the early detection of cervical cancer is expected to drive the market for cervical cancer diagnostics.Increasing awareness among women about cervical cancer along with the emphasis by worldwide cancer organizations and governments on early testing for detecting cervical cancer and preventing it contributes to the growth of the market.
For instance, in August 2018, the United States Preventive Services Task Force has updated its screening guidelines for cervical cancer, which specifies that women between ages 21 to 29 should be screened with a Pap test every 3 years, women between ages 30 to 65 should be screened with any of three tests, namely high-risk HPV testing alone, Pap and high-risk HPV contesting for every 5 years and Pap test alone for every 3 years. The rising adoption of cervical cancer diagnostic tests and emphasis on early diagnosis propels the market.
The increased use of HPV vaccination is anticipated to hinder the cervical cancer diagnostics market.According to the World Health Organization, the 2 HPV types (16 and 18) cause 70% of cervical cancers and pre-cancerous cervical lesions, thereby giving human papillomavirus (HPV) vaccine is effectively reducing the numbers of cervical pre-cancerous lesions that may develop into cervical cancers.
The study published in Cancer Epidemiology, Biomarkers & Prevention, in February 2019 supported the information from the Centers for Disease Control and Prevention (CDC) that states that among women who had been vaccinated, the share of precancers caused by HPV 16 and 18 dropped from 55.2% to 33.3% whereas, in unvaccinated women, the proportion dropped from 51% to 47.3%. The HPV vaccine is recommended by the Centers for Disease Control and Prevention (CDC) for all the kids and adults between the ages of 9 to 26. Therefore, the increased use of HPV vaccination is predicted to hinder the cervical cancer diagnostics market.
Our reports have been used by over 10K customers, including:
372 pages •
By Global Industry Analysts
• Apr 2021
- Global Cervical Cancer Treatment Market to Reach $9.8 Billion by 2027
- Amid the COVID-19 crisis, the global market for Cervical Cancer Treatment estimated at US$7 Billion in the year 2020, is projected to reach a revised size of US$9.8 Billion by 2027, growing at a CAGR of 4.8% over the analysis period...
The Global Oncology Partnering 2015-2021: Deal trends, players and financials report provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Oncology partnering deals Financial deal terms for headline, upfront and royalty...
Global Flow Cytometry in Oncology Market to Reach $5.25 Billion by 2031 Market Report Coverage - Flow Cytometry in Oncology Market Segmentation • Product Type – Assays and Kits, Instruments, Reagents and Consumables, and Software • Technology – Cell-Based and Bead-Based • Type of...
“Gastrointestinal Stromal Tumors - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type,...
Refractory Multiple Myeloma (Oncology) - Drugs in Development, 2021 Summary Refractory Multiple Myeloma (Oncology) - Drugs in Development, 2021 provides an overview of the Refractory Multiple Myeloma pipeline landscape. The report provides comprehensive information on the therapeutics under...
Pituitary Tumor (Oncology) - Drugs in Development, 2021 Summary Pituitary Tumor (Oncology) - Drugs in Development, 2021 provides an overview of the Pituitary Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pituitary Tumor, complete...
Pleomorphic Liposarcoma (Oncology) - Drugs in Development, 2021 Summary Pleomorphic Liposarcoma (Oncology) - Drugs in Development, 2021 provides an overview of the Pleomorphic Liposarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development...
Angiosarcoma (Oncology) - Drugs in Development, 2021 Summary Angiosarcoma (Oncology) - Drugs in Development, 2021 provides an overview of the Angiosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Angiosarcoma, complete with...
Ubiquitin Protein Ligase E3A (Renal Carcinoma Antigen NY REN 54 or Human Papillomavirus E6 Associated Protein or Oncogenic Protein Associated Protein E6 AP or E6AP Ubiquitin Protein Ligase or UBE3A or EC 188.8.131.52) - Drugs in Development, 2021 Summary Ubiquitin Protein Ligase E3A (Renal Carcinoma...
198 pages •
By Global Industry Analysts
• Apr 2021
- Global Doxorubicin Market to Reach $1.4 Billion by 2027
- Amid the COVID-19 crisis, the global market for Doxorubicin estimated at US$1 Billion in the year 2020, is projected to reach a revised size of US$1.4 Billion by 2027, growing at a CAGR of 5.2% over the analysis period 2020-2027. Breast Cancer,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.